An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens

Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.

Marc Dellian, Dai Fukumura, Michael Leunig et al. · PubMed · 1995 · 1.7K citations

Medicine, Cancer Biology, Oncology +17

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

Pharmacy, Oncology, Pharmacology +17

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar et al. · Journal of Clinical Oncology · 2019 · 626 citations · Full text

Medicine, Oncology, Pharmacology +17

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

Michael M. Schmidt, K. Dane Wittrup · Molecular Cancer Therapeutics · 2009 · 574 citations · Full text

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers

Thomas M. Cardillo, Serengulam V. Govindan, Robert M. Sharkey et al. · Bioconjugate Chemistry · 2015 · 296 citations

Medicine, Oncology, Pharmacology +17